Dexcom Eyes International CGM Markets for 2026 Growth

Dexcom's new CEO, Jake Leach, plans to focus on international growth in 2026, leveraging the company's leadership in the US to expand access and coverage for continuous glucose monitors (CGMs) globally. Dexcom held a 44.7% market share in the US in 2025, but Abbott dominated other regions. Leach expects the planned release of trial results from a large non-insulin patient study to contribute to global expansion and growth. Dexcom achieved FY25 revenues of $4.66bn, a 16% increase from FY24, and expects $5.25bn in FY26 revenues.